<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="214341">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295620</url>
  </required_header>
  <id_info>
    <org_study_id>1033AU/0003</org_study_id>
    <secondary_id>ABCSG 16</secondary_id>
    <secondary_id>D5392L00016</secondary_id>
    <secondary_id>SALSA</secondary_id>
    <nct_id>NCT00295620</nct_id>
  </id_info>
  <brief_title>Secondary Adjuvant Long Term Study With Arimidex</brief_title>
  <acronym>SALSA</acronym>
  <official_title>A Prospective, Randomized, Open, Multicentre Phase III-study to Assess the Efficacy of Secondary Adjuvant Endocrine Anastrozole Therapy for 2 Further Yrs vs 5 Further Yrs in Patients With HR +ve Breast Cancer After 5-yr Primary Adjuvant Endocrine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study assesses the effect of further 2 years vs further 5 years of adjuvant treatment
      with anastrozole after initial 5 years of adjuvant endocrine therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABCSG 16 S.A.L.S.A is assessing the effect of further 2 years vs further 5 years of adjuvant
      treatment with anastrozole after initial 5 years of adjuvant endocrine therapy. S.A.L.S.A.
      is a randomized open multicentered phase III study comparing the efficacy of secondary
      adjuvant endokrine treatment of Arimidex® (Anastrozol) for 2 or 5 years after primary
      adjuvant endokrine therapy in patients with hormonreceptor positive mammakarzinom. Patients
      are examined at screening, after 6 months, then every year until 5 years. The subsequent
      yearly follow up with mammographie and clinical examination ends 10 years after the
      screening. S.A.L.S.A. started in February 2004 and has recruited 3484 patients until June
      2010 at 78 sites all over Austria.

      Primary Endpoint:

      1. Proof of the effect of 2 years versus 5 years of Anastrozol after 5 years of adjuvant
      endocrine therapy on the disease free survival

      Secondary endpoint:

        1. Proof of the effect of 2 years versus 5 years of Anastrozol after 5 years of adjuvant
           endocrine therapy on the overall survival

        2. Comparison of fracture rate in both therapy groups

        3. Comparison of incidence of

             1. a secondary carcinoma except the contralateral mammacarcinoma

             2. contralateral mammacarcinoma in both therapie groups
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2004</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the effect in terms of DFS of 2 further years of anastrozole treatment vs further 5 years of adjuvant anastrozole treatment, following 5 years of adjuvant endocrine treatment</measure>
    <time_frame>throughout study (approx 15 years)</time_frame>
    <description>Proof of the effect of 2 years versus 5 years of Anastrozol after 5 years of adjuvant endocrine therapy on the disease free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of overall survival rate, rate of fracture occurrence, occurrence of secondary carcinoma and contralateral breast cancer in the two treatment groups</measure>
    <time_frame>throughout study (approx 15 years)</time_frame>
    <description>Proof of the effect of 2 years versus 5 years of Anastrozol after 5 years of adjuvant endocrine therapy on the overall survival
Comparison of fracture rate in both therapy groups
Comparison of incidence of
a secondary carcinoma except the contralateral mammacarcinoma
contralateral mammacarcinoma in both therapie groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Anastrozol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg per day for 2 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Anastrozol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg per day for 5 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>1mg tablet daily</description>
    <arm_group_label>Arm A: Anastrozol</arm_group_label>
    <arm_group_label>Arm B: Anastrozol</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Postmenopausal patients with histologically confirmed, local radically treated
             invasive or minimal-invasiv Mammacarcinom with or without previous chemotherapie
             and/or radiotherapie.

          2. No distant metastasis at randomization

          3. No relapse at randomization

          4. TNM- classification at time of diagnosis: T1-3, N0 and N+, M0

          5. Estrogen- and or progesterone positive before the beginningof primary endocrine
             therapy

          6. Endocrine therapy for 5 years (maximum deviation ±12 months)

          7. Therapy break (from the preliminary therapie) maximum 12 months.

          8. Informed Consent before the randomisation

        Exclusion criteria:

          1. Premenopausal patients or patients with non definable menopausal statusat time of
             randomisation

          2. Apparent secondary malignant tumor or status after secondary malignant tumor
             (Exceptions: simultaniously appearing bilateral breast carcinoma, estrogen- and or
             progesteronereceptor positive on both sides at the time of diagnosis; in situ
             carcinomaof the cervix and basal cell carcinoma of the skin)

          3. General contraindication respectively hypersensitivity to Anastrozol.

          4. In-situ carcinoma of any size with or without Mb. Paget of the Mamilla respectively
             T4 tumor at the time of first diagnosis.

          5. Receptor unknown or negative at time of diagnosis respectively at beginning of
             primary endocrine therapy

          6. Known liver- and/or kidneyinsufficiency

          7. Performance Index &gt;2 according to WHO

          8. Regular intake of hormon supplement as well as Hormone Replacement Therapy (HRT) more
             than 6 months since primary surgery of the mamma carcinoma

          9. Serious accessory disease, that prevents the adjuvant therapy according to protocol
             and/or the regular follow-up care.

         10. Lacking compliance of the patient

         11. Legal incompetence and/or other circumstances, that prevent the patient from
             understanding the nature, meaning and consequences of the clinical trial

         12. Existing psychiatrical diseaseaccording to ICD (especially alcohol addiction) et the
             time of admission into the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Austria Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amstetten</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Ischl</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baden</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bregenz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dornbirn</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eisenstadt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Feldbach</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Feldkirch</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freistadt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fuerstenfeld</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gmunden</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guessing</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hainburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hall in Tirol</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kirchdorf</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Klagenfurt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krems</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kufstein</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lienz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mistelbach</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moedling</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neunkirchen</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oberpullendorf</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oberwart</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ried im Innkreis</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rottenmann</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scheibbs</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schladming</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schwarzach</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Poelten</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Veit an der Glan</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Steyr</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villach</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Voecklabruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waidhofen an der Thaya</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Weiz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wiener Neustadt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wolfsberg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zams</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>February 23, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hormone receptor positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
